BuyandBill/Alchemy Health Solutions
The $250 Billion Gross-to-Net Bubble
Whether you’re a health insurance provider, physician or patient, you’ve probably noticed an increase in drug list prices over the last few years or more. However, as you may or may not know, the increase in these drug list prices only tells part of the story.
Understanding Rising Specialty Drug Costs and The Effect On Drug Prices
When the U.S. Food and Drug Administration approved two cell-based gene therapies for treating sickle cell disease(SCD) in late 2023, the first question was how much a gene-based treatment for SCD would cost.
What to Know About the FDA-Approved EYLEA (aflibercept) Biosimilars
The Food and Drug Administration(FDA) approved two interchangeable EYLEA biosimilars on Monday, May 20th. This encourages the potential for greater patient accessibility to drugs for the treatment of wet age-related macular degeneration, macular edema, diabetic retinopathy, and other ophthalmic conditions.